Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.81+0.01 (+1.06%)
Close on Nov 17, 2026Market cap $104.43MP/E –Yield –
Organogenesis total assets
Total assets on the balance sheet at the end of each period.
Organogenesis's total assets was $406.45M at Jun 30, 2026. For fiscal 2025 it was $598.73M, up 20.3% from the year before. Over ten years it grew 106.9% a year on average. The highest annual figure on record is $598.73M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $598.73M | +20.3% |
| FY2024 | Dec 31, 2024 | $497.89M | +8.2% |
| FY2023 | Dec 31, 2023 | $460.03M | +2.4% |
| FY2022 | Dec 31, 2022 | $449.36M | +1.4% |
| FY2021 | Dec 31, 2021 | $443.26M | +52.7% |
| FY2020 | Dec 31, 2020 | $290.22M | +31.5% |
| FY2019 | Dec 31, 2019 | $220.69M | +34.8% |
| FY2018 | Dec 31, 2018 | $163.68M | +10.1% |
| FY2017 | Dec 31, 2017 | $148.72M | -52.2% |
| FY2016 | Dec 31, 2016 | $311.44M | +74715.7% |
| FY2015 | Dec 31, 2015 | $416.27K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $406.45M | -11.9% |
| Q1 FY2026 | Mar 31, 2026 | $519.99M | +11.3% |
| Q4 FY2025 | Dec 31, 2025 | $598.73M | +20.3% |
| Q3 FY2025 | Sep 30, 2025 | $509.83M | +14.2% |
| Q2 FY2025 | Jun 30, 2025 | $461.13M | +4.1% |
| Q1 FY2025 | Mar 31, 2025 | $467.39M | +1.9% |
| Q4 FY2024 | Dec 31, 2024 | $497.89M | +8.2% |
| Q3 FY2024 | Sep 30, 2024 | $446.30M | -3.5% |
| Q2 FY2024 | Jun 30, 2024 | $443.16M | -1.6% |
| Q1 FY2024 | Mar 31, 2024 | $458.48M | +2.8% |
| Q4 FY2023 | Dec 31, 2023 | $460.03M | +2.4% |
| Q3 FY2023 | Sep 30, 2023 | $462.65M | +1.2% |
| Q2 FY2023 | Jun 30, 2023 | $450.31M | -1.3% |
| Q1 FY2023 | Mar 31, 2023 | $446.11M | +2.3% |
| Q4 FY2022 | Dec 31, 2022 | $449.36M | +1.4% |
| Q3 FY2022 | Sep 30, 2022 | $457.27M | +23.4% |
| Q2 FY2022 | Jun 30, 2022 | $456.36M | +28.3% |
| Q1 FY2022 | Mar 31, 2022 | $436.27M | +36.7% |
| Q4 FY2021 | Dec 31, 2021 | $443.26M | +52.7% |
| Q3 FY2021 | Sep 30, 2021 | $370.42M | +50.3% |
| Q2 FY2021 | Jun 30, 2021 | $355.56M | +64.2% |
| Q1 FY2021 | Mar 31, 2021 | $319.18M | +53.2% |
| Q4 FY2020 | Dec 31, 2020 | $290.22M | +31.5% |
| Q3 FY2020 | Sep 30, 2020 | $246.43M | +41.1% |
| Q2 FY2020 | Jun 30, 2020 | $216.49M | +28.8% |
| Q1 FY2020 | Mar 31, 2020 | $208.34M | +18.1% |
| Q4 FY2019 | Dec 31, 2019 | $220.69M | +34.8% |
| Q3 FY2019 | Sep 30, 2019 | $174.64M | -44.8% |
| Q2 FY2019 | Jun 30, 2019 | $168.07M | -46.6% |
| Q1 FY2019 | Mar 31, 2019 | $176.45M | -43.8% |
| Q4 FY2018 | Dec 31, 2018 | $163.68M | +10.1% |
| Q3 FY2018 | Sep 30, 2018 | $316.31M | +1.4% |
| Q2 FY2018 | Jun 30, 2018 | $314.98M | +1.1% |
| Q1 FY2018 | Mar 31, 2018 | $313.79M | +0.8% |
| Q4 FY2017 | Dec 31, 2017 | $148.72M | -52.2% |
| Q3 FY2017 | Sep 30, 2017 | $312.06M | +37868.8% |
| Q2 FY2017 | Jun 30, 2017 | $311.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $311.24M | – |
| Q4 FY2016 | Dec 31, 2016 | $311.44M | – |
| Q3 FY2016 | Sep 30, 2016 | $821.88K | – |
See a number that looks wrong?